Guggenheim raised the firm’s price target on Revolution Medicines (RVMD) to $205 from $175 and keeps a Buy rating on the shares after the company reported Q1 results and highlighted the recent milestone success of the Phase 3 RASolute 302 study in second-line PDAC. The firm is updating its model and estimates to reflect Q1 results, including incorporating NSCLC into its revenue model for zoldonrasib following recent data and increasing its view of the odds of success in first-line PDAC for daraxonrasib and zoldonrasib.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Ami Fadia Reiterates Buy on Revolution Medicines, Slightly Lowers Price Target to $183 Amid Higher Non‑Cash Expenses and Expanded RASolute 301 Trial
- Revolution Medicines reports Q1 EPS ($2.29), consensus ($1.84)
- Revolution Medicines sees FY26 operating expenses of $1.7B-$1.8B
- Revolution Medicines announces NEJM publication of data on Daraxonrasib
- Revolution Medicines: Buy Rating Reiterated as Pipeline Advances, Trial Upsized, and $263 Price Target Maintained